Literature DB >> 26237430

The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.

Vincent-Philippe Lavallée1,2, Irène Baccelli1, Jana Krosl1, Brian Wilhelm1,3, Frédéric Barabé1,4,5, Patrick Gendron1, Geneviève Boucher1, Sébastien Lemieux1,6, Anne Marinier1,7, Sylvain Meloche8,9, Josée Hébert1,2,3,10, Guy Sauvageau1,2,3,10.   

Abstract

Using next-generation sequencing of primary acute myeloid leukemia (AML) specimens, we identified to our knowledge the first unifying genetic network common to the two subgroups of KMT2A (MLL)-rearranged leukemia, namely having MLL fusions or partial tandem duplications. Within this network, we experimentally confirmed upregulation of the gene with the most subtype-specific increase in expression, LOC100289656, and identified cryptic MLL fusions, including a new MLL-ENAH fusion. We also identified a subset of MLL fusion specimens carrying mutations in SPI1 accompanied by inactivation of its transcriptional network, as well as frequent RAS pathway mutations, which sensitized the leukemias to synthetic lethal interactions between MEK and receptor tyrosine kinase inhibitors. This transcriptomics-based characterization and chemical interrogation of human MLL-rearranged AML was a valuable approach for identifying complementary features that define this disease.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26237430     DOI: 10.1038/ng.3371

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  42 in total

1.  Identification of small molecules that support human leukemia stem cell activity ex vivo.

Authors:  Caroline Pabst; Jana Krosl; Iman Fares; Geneviève Boucher; Réjean Ruel; Anne Marinier; Sébastien Lemieux; Josée Hébert; Guy Sauvageau
Journal:  Nat Methods       Date:  2014-02-23       Impact factor: 28.547

2.  High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia.

Authors:  V Grossmann; S Schnittger; F Poetzinger; A Kohlmann; A Stiel; C Eder; A Fasan; W Kern; T Haferlach; C Haferlach
Journal:  Leukemia       Date:  2013-03-28       Impact factor: 11.528

3.  C/EBP-beta, C/EBP-delta, PU.1, AML1 genes: mutational analysis in 381 samples of hematopoietic and solid malignancies.

Authors:  Vijaya Vegesna; Seisho Takeuchi; Wolf-K Hofmann; Takayuki Ikezoe; Sigal Tavor; Utz Krug; Anthony C Fermin; Anthony Heaney; Carl W Miller; H Phillip Koeffler
Journal:  Leuk Res       Date:  2002-05       Impact factor: 3.156

Review 4.  The MLL partial tandem duplication in acute myeloid leukaemia.

Authors:  Jorg Basecke; Jarrett T Whelan; Frank Griesinger; Fred E Bertrand
Journal:  Br J Haematol       Date:  2006-09-11       Impact factor: 6.998

5.  Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.

Authors:  E Beillard; N Pallisgaard; V H J van der Velden; W Bi; R Dee; E van der Schoot; E Delabesse; E Macintyre; E Gottardi; G Saglio; F Watzinger; T Lion; J J M van Dongen; P Hokland; J Gabert
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

6.  Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Authors:  Stefan Gröschel; Richard F Schlenk; Jan Engelmann; Veronika Rockova; Veronica Teleanu; Michael W M Kühn; Karina Eiwen; Claudia Erpelinck; Marije Havermans; Michael Lübbert; Ulrich Germing; Ingo G H Schmidt-Wolf; H Berna Beverloo; Gerrit J Schuurhuis; Gert J Ossenkoppele; Brigitte Schlegelberger; Leo F Verdonck; Edo Vellenga; Gregor Verhoef; Peter Vandenberghe; Thomas Pabst; Mario Bargetzi; Jürgen Krauter; Arnold Ganser; Peter J M Valk; Bob Löwenberg; Konstanze Döhner; Hartmut Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

7.  Gene expression profiling of pediatric acute myelogenous leukemia.

Authors:  Mary E Ross; Rami Mahfouz; Mihaela Onciu; Hsi-Che Liu; Xiaodong Zhou; Guangchun Song; Sheila A Shurtleff; Stanley Pounds; Cheng Cheng; Jing Ma; Raul C Ribeiro; Jeffrey E Rubnitz; Kevin Girtman; W Kent Williams; Susana C Raimondi; Der-Cherng Liang; Lee-Yung Shih; Ching-Hon Pui; James R Downing
Journal:  Blood       Date:  2004-06-29       Impact factor: 22.113

8.  PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain.

Authors:  Wendy D Cook; Benjamin J McCaw; Christopher Herring; Deborah L John; Simon J Foote; Stephen L Nutt; Jerry M Adams
Journal:  Blood       Date:  2004-08-10       Impact factor: 22.113

9.  A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.

Authors:  Timothy J Ley; Patrick J Minx; Matthew J Walter; Rhonda E Ries; Hui Sun; Michael McLellan; John F DiPersio; Daniel C Link; Michael H Tomasson; Timothy A Graubert; Howard McLeod; Hanna Khoury; Mark Watson; William Shannon; Kathryn Trinkaus; Sharon Heath; James W Vardiman; Michael A Caligiuri; Clara D Bloomfield; Jeffrey D Milbrandt; Elaine R Mardis; Richard K Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-12       Impact factor: 11.205

10.  The MLL recombinome of acute leukemias in 2013.

Authors:  C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal:  Leukemia       Date:  2013-04-30       Impact factor: 11.528

View more
  64 in total

1.  Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations.

Authors:  V-P Lavallée; S Lemieux; G Boucher; P Gendron; I Boivin; S Girard; J Hébert; G Sauvageau
Journal:  Leukemia       Date:  2016-02-09       Impact factor: 11.528

2.  Pharmacological inhibition of the transcription factor PU.1 in leukemia.

Authors:  Iléana Antony-Debré; Ananya Paul; Joana Leite; Kelly Mitchell; Hye Mi Kim; Luis A Carvajal; Tihomira I Todorova; Kenneth Huang; Arvind Kumar; Abdelbasset A Farahat; Boris Bartholdy; Swathi-Rao Narayanagari; Jiahao Chen; Alberto Ambesi-Impiombato; Adolfo A Ferrando; Ioannis Mantzaris; Evripidis Gavathiotis; Amit Verma; Britta Will; David W Boykin; W David Wilson; Gregory Mk Poon; Ulrich Steidl
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

3.  MLL leukemia induction by t(9;11) chromosomal translocation in human hematopoietic stem cells using genome editing.

Authors:  Corina Schneidawind; Johan Jeong; Dominik Schneidawind; In-Suk Kim; Jesús Duque-Afonso; Stephen Hon Kit Wong; Masayuki Iwasaki; Erin H Breese; James L Zehnder; Matthew Porteus; Michael L Cleary
Journal:  Blood Adv       Date:  2018-04-24

4.  The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.

Authors:  Shuhui Jiang; Yi Fan; Yanglan Fang; Chang Hou; Jia Chen; Jiannong Cen; Huiying Qiu; Suning Chen; Yang Xu; Depei Wu
Journal:  Bone Marrow Transplant       Date:  2020-09-05       Impact factor: 5.483

5.  Coordination of Myeloid Differentiation with Reduced Cell Cycle Progression by PU.1 Induction of MicroRNAs Targeting Cell Cycle Regulators and Lipid Anabolism.

Authors:  Lauren A Solomon; Shreya Podder; Jessica He; Nicholas L Jackson-Chornenki; Kristen Gibson; Rachel G Ziliotto; Jess Rhee; Rodney P DeKoter
Journal:  Mol Cell Biol       Date:  2017-05-02       Impact factor: 4.272

6.  Mutational landscape and clinical outcome of patients with de novo acute myeloid leukemia and rearrangements involving 11q23/KMT2A.

Authors:  Marius Bill; Krzysztof Mrózek; Jessica Kohlschmidt; Ann-Kathrin Eisfeld; Christopher J Walker; Deedra Nicolet; Dimitrios Papaioannou; James S Blachly; Shelley Orwick; Andrew J Carroll; Jonathan E Kolitz; Bayard L Powell; Richard M Stone; Albert de la Chapelle; John C Byrd; Clara D Bloomfield
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-05       Impact factor: 11.205

7.  Functional interdependence of BRD4 and DOT1L in MLL leukemia.

Authors:  Omer Gilan; Enid Y N Lam; Isabelle Becher; Dave Lugo; Ester Cannizzaro; Gerard Joberty; Aoife Ward; Meike Wiese; Chun Yew Fong; Sarah Ftouni; Dean Tyler; Kym Stanley; Laura MacPherson; Chen-Fang Weng; Yih-Chih Chan; Margherita Ghisi; David Smil; Christopher Carpenter; Peter Brown; Neil Garton; Marnie E Blewitt; Andrew J Bannister; Tony Kouzarides; Brian J P Huntly; Ricky W Johnstone; Gerard Drewes; Sarah-Jane Dawson; Cheryl H Arrowsmith; Paola Grandi; Rab K Prinjha; Mark A Dawson
Journal:  Nat Struct Mol Biol       Date:  2016-06-13       Impact factor: 15.369

8.  A Dysregulated DNA Methylation Landscape Linked to Gene Expression in MLL-Rearranged AML.

Authors:  Michael A Koldobskiy; Jordi Abante; Garrett Jenkinson; Elisabet Pujadas; Ashley Tetens; Feifei Zhao; Rakel Tryggvadottir; Adrian Idrizi; Andreas Reinisch; Ravindra Majeti; John Goutsias; Andrew P Feinberg
Journal:  Epigenetics       Date:  2020-02-29       Impact factor: 4.528

9.  SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.

Authors:  J Bu; A Chen; X Yan; F He; Y Dong; Y Zhou; J He; D Zhan; P Lin; Y Hayashi; Y Sun; Y Zhang; Z Xiao; H L Grimes; Q F Wang; G Huang
Journal:  Leukemia       Date:  2017-11-29       Impact factor: 11.528

10.  Clinical features and gene- and microRNA-expression patterns in adult acute leukemia patients with t(11;19)(q23;p13.1) and t(11;19)(q23;p13.3).

Authors:  B Bhatnagar; J S Blachly; J Kohlschmidt; A-K Eisfeld; S Volinia; D Nicolet; A J Carroll; A W Block; J E Kolitz; R M Stone; K Mrózek; J C Byrd; C D Bloomfield
Journal:  Leukemia       Date:  2015-12-16       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.